Docetaxel,Cisplatin,and Fluorouracil (TCF) for Head and Neck Cancers

Abouzaid S. , Solimando D.A. , Waddell J.A. Cancer chemotherapy update: docetaxel, cisplatin, and fluorouracil (DCF) regimen for head and neck and advanced gastric cancers. Hosp Pharm. 2008; 43(4): 266–276.

Posner M.R. , Hershock D.M. , Blajman C.R. ; TAX 324 Study Group. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer. N Engl J Med. 2007; 357(17): 1705–1715.

Baghi M. , Hambek M. , May A. , Radeloff A. , Gstoettner W. , Knecht R. Adjuvant docetaxel, cisplatin and 5-fluororuacil (TPF) in locally advanced squamous cell carcinoma of the head and neck. Anticancer Res. 2006; 26(1B): 559–563.

Baghi M. , Hambek M. , Wagenblast J. , May A. , Gstoettner W. , Knecht R. A phase II trial of docetaxel, cisplatin and 5-fluorouracil in patients with recurrent squamous cell carcinoma of the head and neck (SCCHN). Anticancer Res. 2006; 26(1B): 585–590.

Posner M.R. , Norris C.M. , Wirth L.J. ; TAX 324 Study Group. Sequential therapy for the locally advanced larynx and hypopharynx cancer subgroup in TAX 324: survival, surgery, and organ preservation. Ann Oncol. 2009; 20(5): 921–927.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Head and neck cancers. v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/head-and-neck.pdf. Published 2010. Accessed March 20, 2010.

Institute for Safe Medication Practices. FDA Advise-ERR: medication errors associated with Taxotere and Taxol. ISMP Medication Safety Alert! Acute Care Edition. http://www.ismp.org/Newsletters/acutecare/articles/19970924.asp. Published February 7, 2001. Accessed March 20, 2010.

Savarese D. , Taplin M.E. , Halabi S. , Hars V. , Kreis W. , Vogelzegang N. A phase II study of docetaxel (Taxotere), estramustine, and low-dose hydrocortisone in men with hormone-refractory prostate cancer: preliminary results of Cancer and Leukemia Group B trial 9780. Semin Oncol. 1999; 26(5)(suppl 17): 39–44.

Hesketh P.J. , Kris M.G. , Grunberg S.M. Proposal for classifying the acute emetogenicity of cancer chemotherapy. J Clin Oncol. 1997; 15(1): 103–109.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Antiemesis. v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/antiemesis.pdf. Published 2010. Accessed March 20, 2010.

Kris M.G. , Hesketh P.J. , Somerfield M.R. ; American Society of Clinical Oncology. American Society of Clinical Oncology guideline for antiemetics in oncology: update 2006. J Clin Oncol. 2006; 24(18): 2932–2947.

Multinational Association for Supportive Care in Cancer. Antiemetic guidelines. http://data.memberclicks.com/site/mascc/MASCC_Guidelines_Update.pdf. Updated March 2008. Accessed March 20, 2010.

Kris M.G. , Gralla R.J. , Clark R.A. Incidence, course, and severity of delayed nausea and vomiting following the administration of high-dose cisplatin. J Clin Oncol. 1985; 3(10): 1379–1384.

Geling O. , Eichler H.G. Should 5-hydroxytryptamine-3 receptor antagonists be administered beyond 24 hours after chemotherapy to prevent delayed emesis? Systematic re-evaluation of clinical evidence and drug cost implications. J Clin Oncol. 2005; 23(6): 1289–1294.

Terrey J.P. , Aapro M.S. The activity of granisetron in patients who had previously failed ondansetron antiemetic therapy. Eur J Clin Res. 1996; 8: 281–288.

Carmichael J. , Keizer H.J. , Cupissol D. , Milliez J. , Scheidel P. , Schindler A.E. Use of granisetron in patients refractory to previous treatment with antiemetics. Anticancer Drugs. 1998; 9(5): 381–385.

de Wit R. , de Boer A.C. , vd Linden G.H. , Stoter G. , Sparreboom A. , Verweij J. Effective cross-over to granisetron after failure to ondansetron, a randomized double blind study in patients failing ondansetron plus dexamethasone during the first 24 hours following highly emetogenic chemotherapy. Br J Cancer. 2001; 85(8): 1099–1101.

Smith IE; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving cytostatic chemotherapy. J Cancer Res Clin Oncol. 1993; 119(6): 350–354.

Soukop M; Granisetron Study Group. A dose-finding study of granisetron, a novel antiemetic, in patients receiving high-dose cisplatin. Support Care Cancer. 1994; 2(3): 177–183.

Cornelison T.L. , Reed E. Nephrotoxicity and hydration management for cisplatin, carboplatin, and ormaplatin. Gynecol Oncol. 1993; 50(2): 147–158.

Kintzel P.E. Anticancer drug-induced kidney disorders. Drug Saf. 2001; 24(1): 19–38.

Weiss R.B. Hypersensitivity reactions. Semin Oncol. 1992; 19(5): 458–477.

Zanotti K.M. , Markham M. Prevention and management of antineoplastic-induced hypersensitivity reactions. Drug Saf. 2001; 24(10): 767–779.

Taxotere [package insert]. Bridgewater, NJ: sanofi-aventis Pharmaceuticals Inc; 2008. http://products.sanofi-aventis.us/taxotere/taxotere.html. Accessed March 20, 2010.

Smith T.J. , Khatcheressian J. , Lyman G.H. 2006 update of recommendations for the use of white blood cell growth factors: an evidence-based clinical practice guideline. J Clin Oncol. 2006; 24(19): 3187–3205.

National Comprehensive Cancer Network. NCCN clinical practice guidelines in oncology. Myeloid growth factors. v.1.2010. http://www.nccn.org/professionals/physician_gls/PDF/myeloid_growth.pdf. Published 2010. Accessed March 20, 2010.

Larson D.L. Treatment of tissue extravasation by antitumor agents. Cancer. 1982; 49(9): 1796–1799.

Larson D.L. What is the appropriate management of tissue extravasation by antitumor agents? Plast Reconstr Surg. 1985; 75(3): 397–405.

Mullin S. , Beckwith M.C. , Tyler L.S. Prevention and management of antineoplastic extravasation injury. Hosp Pharm. 2000; 35(1): 57–74.

Maroun J.A. , Anthony L.B. , Blais N. Prevention and management of chemotherapy-induced diarrhea in patients with colorectal cancer: a consensus statement by the Canadian Working Group on Chemotherapy-Induced Diarrhea. Curr Oncol. 2007; 14(1): 13–20.

Benson AB III , Ajani J.A. , Catalano R.B. Recommended guidelines for the treatment of cancer treatment-induced diarrhea. J Clin Oncol. 2004; 22(14): 2918–2926.

Boyiadzis M.M. , Lebowitz P.F. , Frame J.N. , Fojo T. Hematology-ncology Therapy New York, NY: McGraw-Hill; 2007; 570–578.

Aronoff G.R. , Bennett W.M. , Berns J.S. Drug Prescribing in Renal Failure. 5th ed. Philadelphia, PA: American College of Physicians; 2007.

Kintzel P.E. , Dorr R.T. Anticancer drug renal toxicity and elimination: dosing guidelines for altered renal function. Cancer Treat Rev. 1995; 21(1): 33–64.

Floyd J. , Mirza I. , Sachs B. , Perry M.C. Hepatotoxicity of chemotherapy. Semin Oncol. 2006; 33(1): 50–67.

King P.D. , Perry M.C. Hepatotoxicity of chemotherapy. Oncologist. 2001; 6(2): 162–176.